Lys177
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Ubiquitylation Site Page: > Lys177  -  CK2B (human)

Site Information
VHPEYRPkrPANQFV   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12104353

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 )
Disease tissue studied:
leukemia ( 1 ) , acute lymphocytic leukemia ( 1 )
Relevant cell line - cell type - tissue:
DND-41 (T lymphocyte) ( 1 ) , PC3 (prostate cell) ( 3 )

References 

1

Guo A (2010) CST Curation Set: 9183; Year: 2010; Biosample/Treatment: cell line, DND-41/untreated; Disease: acute lymphocytic leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

2

Guo A (2009) CST Curation Set: 8680; Year: 2009; Biosample/Treatment: cell line, Karpas-620/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Antibodies Used to Purify Peptides prior to LCMS: Ubiquitin (D4A7A10) XP(R) Rabbit mAb Cat#: 3925, PTMScan(R) Ubiquitin Branch Motif (K-e-GG) Immunoaffinity Beads Cat#: 1990
Curated Info

3

Possemato A (2009) CST Curation Set: 8582; Year: 2010; Biosample/Treatment: cell line, PC3/AAG; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG)
Curated Info